The FHCRC PI of the study must approve of enrollment of all patients with pulmonary nodules
Agreement to allow the use of archival tissue from pre-ASCT tumor biopsies\r\n* If unavailable, exceptions may be granted with study principal investigator (PI) approval
Total bilirubin =< . x upper limit of normal (ULN); NOTE: exceptions can be granted from principal investigator (PI) for instances of Gilberts disease, and/or primarily indirect bilirubinemia, if due to recent transfusion and/or hemolysis
Participants who have received treatment with a TKI within  days of the first dose of study treatment; (an alternative appropriate wash-out time based on known duration and time to reversibility of drug related adverse events could be agreed upon by principal investigator and the investigator
NOTE: patients who do not meet the above criteria because of disease involvement of the organ in question, or because of acute systemic illness due to lymphoma, may enroll with permission of the study principal investigator (PI) and approval from the Data Monitoring Committee; this flexibility be allowed due to the heterogeneity of the patient population, the wide range of complications seen in the initial presentation of EBV-related malignancy, and the frequent difficulty encountered in attempting to clearly document that organ dysfunction is the result of an underlying lymphoproliferative disorder
Patients will be included if they have a National Comprehensive Cancer Network score for fatigue over  (NCCN > ) as determined by the standard fatigue scale of - unless otherwise approved by the principle investigator or principal investigator's (PIs) designee
In addition, patients who develop evidence of infection (as determined by history, physical exam or laboratory testing) during the study will be discontinued from the study unless otherwise approved by the PI or PIs designee
Any other intercurrent medical/psychological problem deemed exclusionary by the treating physician or investigators/principal investigator (PI)
Patients who cannot participate in contributing to the neurocognitive outcomes due to severe neurologic impairment or language barrier will be enrolled at the discretion of the treating physician in consultation with the principal investigator (PI)
Participants taking corticosteroids (>=  mg of prednisone or equivalent). Exceptions may be discussed with the overall principal investigator (PI) on a case by case basis
Prior liver radiation therapy (RT) is an exclusion unless subject participation is approved by the principal investigator (PI)
Agreement to allow the use of archival tissue from diagnostic tumor biopsies will be retrieved and submitted post-enrollment \r\n* If unavailable, exceptions may be granted with study principal investigator (PI) approval.
EXPANSION COHORT: There should be a - to -week break between the patients last dose of standard chemotherapy to initiation of the first cycle of study drugs; longer than -week break may be permitted at the discretion of the principal investigator (PI)
Patients with hospitalization within  weeks of treatment initiation date for co-morbid conditions or any complication of disease or therapy that is deemed by the principal investigator as unstable or incompletely treated
Patients will be excluded from Arms A and C if they have received a previous myeloablative transplant; patients who have received a prior HCT at least  months prior may be considered for inclusion on Arms B or D after discussion with the principal investigator (PI)
Any subject who, in the opinion of the principal investigator (PI) is at risk for thromboembolic events
Any other intercurrent medical/psychological problem deemed exclusionary by the treating physician or investigators/principal investigator (PI)
Patients who are in the estimation of the principal investigator (PI), deemed unable or unlikely to adhere to protocol treatment
Any condition or set of circumstances that the principal investigator (PI) or lead associate investigator (LAI) interprets as creating undue risk to the patient by participating on this study or would make the patient unlikely to comply with the study
Clinically significant patient history which in the judgment of the principal investigator (PI) would compromise the patients ability to tolerate high-dose aldesleukin.
Absolute neutrophil count (ANC) < /mm^, per principal investigator (PI) discretion if thought to be related to underlying myeloma
In the opinion of the principal investigator (PI), the participant has a condition that will preclude them from complying with study treatment
No evidence of an active malignancy that would limit the patients survival to less than  years. (If there is any question, the principal investigator [PI] can make a decision).
IDH-R mutated disease status as assessed by local laboratory. HG-producing IDH variants outside of R (i.e. R) may be eligible after discussion with the principal investigator (PI).
Archival tissue for PD-L staining (alternatively a new biopsy [core] at baseline can be used); a minimum of  slides is required (unless approval from the principal investigator [PI] is obtained)
Participants must not have a known additional malignancy that could confuse analysis of on-study treatment; inclusion of all study participants with more than one malignancy must be discussed and approved by the principal investigator (PI)
Patients with active infections. The principal investigator (PI) is the final arbiter of the eligibility;
Clinically significant patient history which in the judgment of the principal investigator (PI) would compromise the patients ability to tolerate high-dose aldesleukin; (Note: At the discretion of the PI, patients enrolled in cohort  may receive low-dose aldesleukin)
Patients must have normal organ and marrow function as defined at the discretion of the treating physician and principal investigator (PI)
Medical or psychological conditions present within  days prior to enrollment that would make the patient unsuitable candidate for cell therapy at the discretion of the principal investigator (PI)
Additional site(s) of active disease (such as parenchymal liver and lung metastases, or supraclavicular nodal metastases), should be considered for treatment (off study) with radiation, surgery, or another form of local therapy, at the discretion of the study principal investigator (PI)
Patients with locally advanced or metastatic RMC histologically confirmed by expert pathology review and loss of SMARCB staining by immunohistochemistry. Patients with advanced or metastatic unclassified renal cell carcinoma with medullary phenotype (a rare SMARCB negative RMC variant occurring in individuals without sickle hemoglobinopathies) are also eligible. The principal investigator (PI) is the final arbiter in questions related to eligibility.
Patients older than  who are deemed fit to receive intensive chemotherapy by the treating physician will be eligible after discussion with the principal investigator (PI).
Note: transfusions are permitted to meet these platelet and hemoglobin criteria if the reason for the cytopenias are judged to be secondary to marrow involvement with tumor per principal investigator (PI) or PI designee
Any mental or physical condition, in the opinion of the PI (or PI designee), which could interfere with the ability of the subject (or the only parent or legal guardian available to care for the subject) to understand or adhere to the requirements of the study
Enrollment in any other treatment studies that would interfere with the endpoints of this study from screening up to  days after the last immunotherapy (EA-NK cells or last infusion of hu.-IL) in the opinion of the PI or PI designee is not permitted
Patients with major symptoms or impairments related to brain metastases, such as aphasia or severe confusion, will be excluded per principal investigator (PI) discretion when those symptoms preclude proper neurocognitive evaluation during the study treatment
Active hepatitis B. Patients with chronic hepatitis B who are on appropriate viral suppressive therapy may be allowed after discussion with the principal investigator (PI).
Patients with active infections; the principal investigator (PI) is the final arbiter of the eligibility
DONOR: Absence of pre-existing donor-specific anti-HLA antibodies (DSA) in the recipient; Patients with pre-existing DSA could undergo desensitization per City of Hope (COH) standard operating procedures [SOP] and should have DS <  prior to conditioning at discretion of principal investigator (PI)
Subjects with prior hypomethylating agent therapy exposure may be eligible based on discussion with the principal investigator (PI)
Patients must not have had prior cancer therapy (including biologic, cytotoxic, and experimental therapies, nitrosoureas, and Gliadel wafers or other surgically implantable antitumor treatment) within  days of registration; if questions arise, please ask the principal investigator (PI)\r\n* NOTE: Patients must not have Novocure within  hours of registration
Newly diagnosed, previously untreated myeloma requiring systemic chemotherapy\r\n* Prior treatment of hypercalcemia or spinal cord compression or active and/or aggressively progressing myeloma with corticosteroids and/or lenalidomide and/or bortezomib/principal investigator (PI)-based regimens does not disqualify the subject (the corticosteroid treatment dose should not exceed the equivalent of  mg of dexamethasone in a  week period or not more than  cycle of lenalidomide and/or PI-based therapy)
Patients with active infections; the principal investigator (PI) is the final arbiter of the eligibility
Patients who have been treated with chemotherapy or radiation within two weeks of planned study enrollment; this does not include hydroxyurea, which may be continued until start of conditioning therapy; ruxolitinib may be continued at principal investigator's discretion during conditioning
No evidence of an active malignancy that would limit the patients survival to less than  years. (If there is any question, the principal investigator [PI] can make a decision)
Progressive disease via Response Evaluation Criteria in Solid Tumors version . (RECIST .) on prior study or standard of care therapy utilizing an immunotherapy agent OR a clinical status that requires salvage radiation treatment (e.g.: palliative radiation therapy [RT]) at the discretion of treating physician and/or principal investigator (PI)
Subjects that have received experimental vaccines or other immune therapies should be discussed with the principal investigator to confirm eligibility
Patients must be able to have fiducials placed; if not, the tumor must be posterior and adjacent to the aorta and treatment will only be permitted at the discretion of the principal investigator
Multi-focal disease (unless pre-approved by principal investigator [PI])
Any co-morbidity or condition of sufficient severity to limit full compliance with the protocol per assessment by the principal investigator
Investigational agent within  days of enrollment without approval from the sponsor- principal investigator (PI)
Any mental or physical condition, in the opinion of the Principal Investigator (PI) (or PI designee), which could interfere with the ability of the subject (or the only parent or legal guardian available to care for the subject) to understand or adhere to the requirements of the study
Patients receiving cytotoxic agents will be evaluated by the PI or his designee for eligibility suitability
Patients older than  who are deemed fit to receive intensive chemotherapy by the treating physician are eligible after discussion with the principal investigator (PI)
Performance status < , unless directly related to disease process as determined by the principal investigator
Other investigational procedures while participating in this study that could affect the primary objective of the study as determined by the principal investigator (PI) are excluded
Principal investigator (PI) to review the exam findings, photos and imaging study and determine whether the patient meets inclusion criteria in the study, based on BCCA size, location of tumor, and clinical assessment score\r\n* Orbital invasion or impending invasion by BCCA\r\n* Medial canthal BCCA within  mm of lacrimal apparatus
Patient will be approached for enrolling in the study by the PI, treating physician or a designee; informed consent will be obtained by the PI, co-investigator (co-I) or a qualified designee
All patients must have histologic demonstration of metastatic or locally unresectable transitional cell carcinoma of the urothelium; variant histology is allowed as long as there is an urothelial component present; the principal investigator (PI), will serve as the final arbiter of eligibility
Any medical or psychological condition or situation deemed by the principal investigator (PI) to put the patient at increased risk of complications or noncompliance
There is a high likelihood that the patient, in the opinion of the principal investigator (PI) or lead associate investigator (LAI), will meet the research phase eligibility criteria and proceed to transplant after induction phase therapy is completed
Life expectancy of at least  weeks in opinion of principal investigator (PI) and/or designee
Performance status =< , unless directly related to disease process as determined by the principal investigator
Abdominal obesity that would, in the assessment of the principal investigator (PI), make the HIFU ablation difficult
Patients with a medical condition or social situation that at the discretion of the Principal Investigator (PI) would preclude them from completion of the trial
Note: exceptions may be made at the discretion of the principal investigator (PI)/study team
Uncontrolled inter-current illness that would limit compliance with study requirements; this will be per the discretion of the treating physician and/or principal investigator (PI)
Active second malignancy that in the opinion of the principal investigator (PI) may interfere with or be adversely affected by this treatment
Any other medical condition(s) that, at the discretion of the principal investigator (PI), would make the patient inappropriate for this study
Patients must not have any significant toxicity associated with prior surgery, radiation therapy, chemotherapy, or immunotherapy, per principal investigator (PI) discretion
Uncontrolled infections; principal investigator (PI) is the final arbiter of this criterion
Active autoimmune disease requiring immunosuppressive therapy is excluded unless discussed with the Principal Investigator (PI)
No prior therapy, unless an emergency situation requires local tumor treatment (discuss with principal investigator [PI])
Patient must be able to have fiducials placed; if not, the tumor must be posterior and adjacent to the aorta and treatment will only be permitted at the discretion of the principal investigator
Medical or psychological conditions that would make the patient unsuitable candidate for cell therapy at the discretion of the principal investigator (PI)
Patients aged <  years who are unsuitable for standard induction therapy may be eligible after discussion with principal investigator (PI)
Patients may have had any number of prior treatment regimens (including biologic) before or after radiotherapy; patients may not have previously been treated with bevacizumab or lapatinib. Gliadel wafers must be approved by CERN Principal Investigator (PI) (Project Leader, Co-Leader and Protocol PI)
One of the following, in order to lower risk of graft rejection: cytotoxic chemotherapy, an adequate course of -azacitidine or decitabine, or alemtuzumab within  months prior to start of conditioning; or previous BMT within  months prior to start of conditioning; Note: patients who have received treatment outside of these windows may be eligible if it is deemed sufficient to reduce graft rejection risk; this will be decided on a case-by-case basis by the Principal Investigator (PI) or co-PI
Patient who is otherwise considered unsuitable for transplant at the discretion of the principal investigator
Patients older than  will be considered for eligibility at the discretion of the principal investigator (PI)
Patients with a severe infection that on evaluation by the Principal Investigator precludes ablative chemotherapy or successful transplantation
Symptomatic, clinically significant autonomic neuropathy which the Principal Investigator (PI) feels will preclude administration of study treatment
Peripheral oedema at Screening that in the opinion of the Prinicpal Investigator (PI) or designee might prevent adequate absorption of subcutaneously administered CPHPC
Have at least stable disease, as determined by the investigator.
History of previous malignancy that in the principal investigator (PI)s opinion has a reasonable chance of recurrence during the study period or otherwise confounding this clinical trial
Locally advanced (including unresectable or borderline resectable) pancreatic cancer based on computed tomography (CT) imaging, as determined by the principal investigator (PI)
THE PATIENT IS INELIGIBLE TO PARTICIPATE IN PART  IF ANY OF THE FOLLOWING OCCUR: Part  data contradict clinical judgment. The investigator should discuss with the principal investigator (PI) and use the best discretion.
It will be at the Principal Investigator's (PIs) discretion to enroll a patient who has a small, asymptomatic brain hemorrhage, but patients who have had symptomatic hemorrhages will be excluded
History of intratumoral or peritumoral hemorrhage if deemed significant by the treating investigator; if there are questions, the treating investigator should contact the study overall principal investigator (P.I.), Eudocia Quant Lee, medical doctor (MD), at -- or eqlee@partners.org
Subjects must be medically fit to undergo surgery determined by the principal investigator (PI)
Patients with liver metastases who do not meet the eligibility parameters may only be enrolled at the discretion of the principal investigator (PI)
Total bilirubin =<  x ULN (patients with Gilbert syndrome may be included at the discretion of the principal investigator [PI] or where hemolysis has been excluded)
Patients with other cardiac diseases may be excluded at the discretion of the principal investigator (PI) following consultation with cardiology consultants
Any AIDS-related opportunistic infection occurring within the past year and for which treatment has been unsuccessful would be considered exclusionary, but this is done on a case-by-case basis as determined by the principal investigator
Any AIDS-related opportunistic infection occurring within the past year and for which treatment has been unsuccessful would be considered exclusionary, but this is done on a case-by-case basis as determined by the principal investigator (PI)
Patients with AML or MDS arising from myeloproliferative neoplasm can be enrolled after principal investigator (PI) approval on case to case basis, depends on the spleen size and degree of bone marrow fibrosis
Patients who have received radiation therapy as part of their leukemia treatment may be ineligible and individual cases must be presented to the study principal investigator (PI) for determination of eligibility
Clinically significant oral cGVHD after allogeneic hematopoietic stem cell transplant (HSCT) with severity score of at least  on erythema subset and/or at least  on ulceration subset and a composite score >=  of the OMRS scale confirmed by the principal investigator (PI), clinical study chair (CSC), or lead associate investigator (LAI)
Subjects with an indication for AHCT for the treatment of PCM as determined by the principal investigator (PI) or lead associate investigator (LAI)\r\n* Subjects following induction treatment for PCM\r\n* Subjects with recurrent or persistent evaluable disease who have not undergone AHCT for the treatment of the PCM
Patients may be excluded at the discretion of the principal investigator (PI) or if it is deemed that allowing participation would represent an unacceptable medical or psychiatric risk
Any condition (psychological, physical or use/abuse of substances) which, in the opinion of the principal investigator (PI) or a sub-investigator (sub-I), would possibly endanger the subject during their participation in the study, or allow for non-compliance with the investigational drug and treatment under study
No concomitant use of alternative complimentary therapies or over the counter (OTC) agents allowed without prior approval of the principal investigator (PI)
Serum total bilirubin < . mg/dl; values above these levels may be accepted, at the discretion of the principal investigator (PI) or lead associate investigator (LAI), if such elevations are thought to be due to liver involvement by malignancy or GVHD
Pathology confirmation of GCT histology at Memorial Sloan-Kettering Cancer Center (MSKCC) or a collaborating treating institution; in exceptional circumstances, patients without pathological diagnosis may be included in the study following discussion with national principal investigator, Dr. Feldman, (or national Co-principal investigator [PI] or MSKCC Co-PI if the national PI is unavailable) if they meet the one of the following criteria:\r\n* Patients with testicular mass (detected clinically and/or by ultrasound), and/or mediastinal or retroperitoneal lymphadenopathy or pineal tumor AND elevated serum tumor markers (human chorionic gonadotropin [HCG] and/or alpha-fetoprotein [AFP]); patients with elevated lactate dehydrogenase (LDH) only will not be included without pathological confirmation of GCT since LDH is a nonspecific marker for GCT and could potentially be elevated in other malignancies such as lymphomas\r\n* Initial treatment without biopsy confirmation is usually recommended and tissue confirmation may be obtained after initiating therapy
Patients <  yrs of age must be discussed on a case by case basis with the primary investigator (PI) of the protocol prior to registration
Limited prior therapy, including systemic glucocorticoids for  week or less,  dose of vincristine, emergency radiation therapy to the mediastinum, and  dose of IT chemotherapy; other circumstances must be cleared by principal investigator (PI) or co-PI
The FHCRC principal investigator (PI) of the study must approve enrollment of all patients with pulmonary nodules
Subjects with pre-existing medical illnesses or medications which might interfere with the study as determined by principal investigator (PI)
Patient must be willing to undergo biopsies as specified by the protocol; the biopsy requirement can only be waived if deemed unsafe by the patients treating physician or the principal investigator (PI)
Subjects with pre-existing medical illnesses or medications which might interfere with the study as determined by principal investigator (PI)
Limited prior therapy, including systemic glucocorticoids for one week or less, one dose of vincristine, emergency radiation therapy to the mediastinum and one dose of intrathecal chemotherapy; other circumstances must be cleared by principal investigator (PI) or co-PI
Toxicity related to prior therapy must either have returned to =< grade , baseline, or been deemed irreversible. Certain non-serious exceptions include alopecia, hypothyroidism, neuropathy, nausea, adrenocortical deficiency requiring physiologic replacement dose of steroids, and other conditions noted and approved by the principal investigator (PI).
Note: Transfusions/infusions to meet eligibility criteria are not allowed but if in the opinion of the Principal Investigator, it is beneficial, the patient may be rescreened after receiving one of these procedures.
Concurrent malignancy requiring active therapy \r\n* Patients with more than one type of lymphoma may be enrolled after discussion with the MSK principal investigator
Stable dose of corticosteroids for  weeks prior to enrollment; exception permitted with overall principal investigator (PI) approval
Prior anti-VEGF directed therapy may be allowed only if approved by the principle investigator (PI)
Patients with second malignancies may be eligible at discretion of principal investigator (PI) given acute life threatening nature of untreated AML or higher risk MDS; patients maintained on long-term non-chemotherapy treatment, e.g., hormonal therapy, are also eligible
Patients with pheochromocytoma/paraganglioma tumors potentially curable by surgical excision alone as determined by the Principal Investigator in discussions with the surgical consultants
Enrollment in a concurrent cancer therapeutic trial will require prior review and approval by the study site principal investigator (PI) to determine that there are no drug interactions concerns
Study team (PI, co-investigator [I], and/or research nurse) may deny enrollment if in the study teams opinion, the candidate may not be adherent to the treatment protocol including scheduled follow-ups
Patients who are unable to return for follow-up visits as required by this study; patients with a history of second malignant tumor, other than the common skin cancers - basal and squamous carcinomas, within the past  years and uncertainty about the histological nature of the metastatic lesions; cases with other types of malignancies should be reviewed and decided by the principal investigator (PI) of the study
Total bilirubin =< the institutional upper limit of normal (exception permitted in patients with Gilberts syndrome after discussion with study principal investigator [PI], on a case by case basis and if liver function tests are within normal limits)
Diagnosis of severe aplastic anemia: eligibility to be discussed with principal investigator (PI) and service chief; such patients will be assessed in Arm B
Patients must be adequately recovered from surgery, radiation therapy, or any surgical complications prior to enrollment; in general, this means patients will be off antibiotics from wound infections and drains removed; however if necessary, patients can be treated with a drain in place at the discretion of the principal investigator (PI) if the  days window is about to expire
Patient must have disease that is easily accessible for a core biopsy as determined by the treating physician or study principal investigator (PI), patient must agree to the mandatory biopsies at baseline and end of cycle  (MTD expansion cohort only, and at the discretion of the PI/PI optional)
Any previous radiation to sites of planned SRS; a patient may be deemed eligible in this case if a non-radiation mode of local ablation such as surgical resection is deemed safe and feasible by the principal investigator (PI)
No uncontrolled infection; protocol principal investigator (PI) or designee will be final arbiter if there is uncertainty regarding whether a previous infection is controlled on appropriate (antibiotic) therapy
Patient may be excluded if, in the opinion of the principal investigator (PI) and investigator team, the patient is not capable of being compliant
AIDS related syndromes or symptoms that pose a perceived excessive risk for transplantation-related morbidity as determined by the principal investigator.
Patients with psychosocial conditions that would prevent study compliance and follow-up, as determined by the principal investigator.
Reasonable expectation that no chemotherapy will be given in the subsequent  months (principal investigator's [PIs] discretion)
Patients with symptomatic cholelithiasis (asymptomatic gall stone discovered on screening ultrasound [US] should be reviewed by the principal investigator [PI] but will not lead to automatic exclusion)
The FHCRC PI of the study must approve of enrollment of all patients with pulmonary nodules
There is a high likelihood that the patient, in the opinion of the principal investigator (PI) will meet the protocols eligibility/enrollment criteria to proceed to transplant after standard therapy is completed
Patients with symptomatic uremia, uncontrolled edema or unstable serum electrolytes should not enter the trial until such time as they have been stabilized  such patients should be discussed with the principal investigator
Laboratory values that would not prevent the patient from receiving chemotherapy as determined by the Principal Investigator (PI) or study oncologist
Subjects older than  years old to be discussed with principal investigator (PI) prior to subject consent; consensus between PI and treating physician is required
Adequate tissue must have been obtained from surgical intervention to satisfy biospecimen requirements of study (collected under biospecimen collection protocols; either AAAO principal investigator [PI]: Yvonne Saenger or AAAR PI: Adrian Sacher)
Prior malignancy is acceptable if the subject is considered to be cured; in most cases this will mean a -year disease-free period; contact the principal investigator for any specific question regarding this requirement
Patient should preferably have received a pre-transplant conditioning with rituximab and carmustine/etoposide/cytarabine/melphalan/Rituxan (BEAM/R); other regimens which are similar may be accepted at the discretion of the principal investigator (PI)
High risk of inability to comply with therapy in the estimation of the principal investigator (PI)
Patients with a history of second malignant tumor, other than the common skin cancers - basal and squamous carcinomas, within the past  years and uncertainty about the histological nature of the metastatic lesions; cases with other types of malignancies should be reviewed and decided by the principal investigator (PI) of the study
No patient may be entered onto the study without consultation with the principal investigator or his designee
Patients with other cardiac diseases may be excluded at the discretion of the principal investigator (PI) following consultation with cardiology consultants
Disease to be treated by ILI must be distal to the planned site of tourniquet placement (which for the leg is generally the apex of the femoral triangle, or for the arm is distal to the deltoid insertion); if provider feels ILI appropriate with disease in these areas, patients may be enrolled with principal investigator (PI) approval
Patients above the age of  only with principal investigator (PI) approval
Other agents used strictly with palliative intent might be allowed during this period after discussing with principal investigator
For leukapheresis, patients must meet the following criteria (any exceptions to this will require prior approval by the apheresis director and principal investigator [PI]):
Patients with active secondary malignancy will not be eligible unless approved by the principal investigator (PI)
Cohort A: Stage IIA-IIIA (TanyNM or Tb-NM) (selected patients with single station N nodal involvement in close proximity to the primary tumor target may be considered eligible at the discretion of the principal investigator [PI] if all normal tissue guidelines can be met)
Regular use of anti-inflammatory agents, with the exception of a baby aspirin regimen per principal investigator's (PI's) discretion
Relapsed, refractory, or progressive Hodgkins lymphoma meeting one of the following criteria, and autologous BMT is not recommend:\r\n* PR or better prior to transplantation\r\n* Stable disease prior to transplantation, provided that the disease is low-volume and disease control is regarded as sufficient to proceed with BMT; eligibility of such patients will be determined on a case-by-case basis with the principal investigator (PI) or co-PI
Patients with active infections; the principal investigator (PI) is the final arbiter of the eligibility
Skin biopsy specimen of representative lesion obtained at screening of study and deemed diagnostic of mycosis fungoides by principal investigator
Patients with other cardiac diseases may be excluded at the discretion of the principal investigator (PI) following consultation with cardiology consultants
Individuals with significant psychiatric disturbance that require a higher level of care; this determination will be at the discretion of the healthcare provider, site principal investigator (PI); as appropriate and determined by the site PI, the study PI may be consulted to discuss determination of participant eligibility
Individuals with substance abuse/dependence problems that require a higher level of care; this determination will be at the discretion of the healthcare provider or site PI; as appropriate and determined by the site PI, the study PI may be consulted to discuss determination of participant eligibility
Is medically, psychiatrically, or otherwise unable to participate (as determined by a physician or study principal investigator [PI])
Subjects with bipolar disorder that have experienced a manic episode within  months of study entry will be excluded or at the principal investigator (PI)s discretion
In the opinion of the principal investigator (PI) or an associate investigator (AI), the subject has significant cognitive or emotional difficulties that would prevent them from being able to understand and/or participate fully in the intervention or the measures
Subjects with significant concurrent medical complications that in the judgment of the principal investigator(s) could affect the patient's ability to complete the planned trial; there are no therapy restrictions or restrictions regarding the use of other investigational agents
In the opinion of the principal investigator (PI), the participant has a condition that will preclude them from complying with study treatment
Medical conditions precluding participation in the intervention or likely to lead to death within  months, as determined by the principal investigator (PI)
NOTE: If such hematologic abnormalities are present and deemed due to the process of cGvHD, these requirements may be waived with the approval of the principal investigator (PI)
Anxiety is principal psychiatric problem
Significantly diseased (as determined by the principal investigator [PI] or treating physician) or obstructed gastrointestinal tract or uncontrolled vomiting or diarrhea
Participants who, in the judgment the study principal investigator (PI), have severe or unstable mental illness which could interfere with participation in the trial
Any mental or physical condition, in the opinion of the principal investigator (PI) or PI designee, which could interfere with the ability of the subject to understand or adhere to the requirements of the study
Ages - (women above the age of  may be included at principal investigator [PI] discretion)
Patients who are receiving other investigational agents will be permitted on study, at the discretion of the principal investigator
Have an acute illness, as determined by the site principal investigator within  hours prior to study vaccination; an acute illness which is nearly resolved with only minor residual symptoms remaining is allowable if, in the opinion of the site principal investigator, the residual symptoms will not interfere with the ability to assess safety parameters as required by the protocol and was not due to an influenza infection
If the study staff or principal investigator (PI) have serious concerns about the participants ability to engage in and/or complete the study protocol.
Significant unstable medical/psychiatric or substance use disorders, or medically/psychiatrically at risk in the judgment of the study physician (or licensed medical professional designated to consult in his absence) or principal investigator (PI)
Reports diagnosis of seizure disorder or a history of neurological illness or closed head injury that in the opinion of the principal investigator (PI) or designated expert(s) feels that it would affect the results of the electroencephalogram (EEG)
Reports diagnosis of seizure disorder or a history of neurological illness or closed head injury that\r\nin the opinion of the principal investigator (PI) feels that it would affect the results of the electroencephalogram (EEG)
Patients must have a hematologic malignancy treatable by nonmyeloablative HCT; the following diseases will be permitted although other diagnoses can be considered if approved by Patient Care Conference (PCC) and the principal investigator:
Subjects with pre-existing medical illnesses or medications which might interfere with the study as determined by principle investigator (PI)
Participants who in the opinion of the principal investigator (PI) will be at higher risk of acetylsalicylic acid (ASA)-related complications
History of intercurrent or past medical or psychiatric illness that would make participation in a research biopsy protocol difficult or not feasible at the discretion of the principal investigator or co-investigator(s)
Uncontrolled illness or comorbidity that in the judgment of the principal investigator (PI) would preclude participation in the study
Patients with reoccurrence of brain tumor\r\n* The principal investigator or co-principal investigator (PI) must review magnetic resonance imaging (MRI) and CT findings based on the radiologic assessment provided they meet the following imaging criteria (as established in the clinical trial -) OR
Prior treatment with bortezomib or other Proteasome Inhibitor (PI) is allowed, provided all of the following criteria are met: Best response achieved with prior bortezomib at any time was ? PR and with the last PI (PI therapy (alone or in combination) was ? PR, AND Participant did not discontinue bortezomib due to ? Grade  related toxicity, AND Must have had at least a -month PI-treatment-free interval prior to Cycle  Day  (CD) of study treatment.
For cohort  only: evidence of disease progression =<  months prior to registration according to RECIST ., as confirmed by the site study principal investigator (PI)
Subjects may be excluded at the discretion of the principal investigator or study team members
The principal investigator determines that the patient is acting in ways that would lessen their chances of completing the study
Is medically or otherwise unable to participate (as determined by a physician or study principal investigator [PI])
Patients suffering from a severe psychiatric disorder or condition that would significantly interfere with study participation, as determined by the principal investigator or by the attending palliative care physician
Displays ability to use and understand the PMSA as evidenced by successful response to alarm and successful entries while monitored by the principal investigator (PI)
Patients who are receiving any other investigational agents; a minimum of  weeks wash-out period is required for eligibility; please contact principal investigator, Dr. Swati Kulkarni for further clarification
